Drug Approval | January 06, 2024
Comprehensive clinical development programs being initiated for each investigational candidate
The congress aims at emphasizing on the most recent trends, advancements in the field of Obstetrics & Gynaecology
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
According to Sun Pharma, the purpose of the strategic investment is to obtain access to the technology for certain compounds and territories while also fostering the development of novel pharmaceutical delivery systems.
The product is expected to be launched in December 2023
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
Receives registration of Valganciclovir powder for oral solution in Germany
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Subscribe To Our Newsletter & Stay Updated
